Mongua-Rodríguez N, Ferreyra-Reyes L, Ferreira-Guerrero E, Delgado-Sánchez G, Martínez-Hernández M, Canizales-Quintero S, Téllez-Vázquez NA, Cruz-Salgado A, Gutiérrez-Robledo LM, García-García L

Language: Spanish
References: 18
Page: 381-394
PDF size: 342.80 Kb.

ABSTRACT

Objective. To estimate the proportion of vaccinated subjects and associated factors in adults and older adults in Mexico. Materials and methods. Analysis of data obtained from the Ensanut Continua 2021-2023 and comparison with the proportion of vaccinated subjects in Ensanut 2012. Results. Given that only 6.8% of adults and older adults in Ensanut Continua 2021-2023 and 17.7% in Ensanut 2012 could accredit their vaccination status, the analysis is based on self-report. When comparing Ensanut Continua 2021-2023 with Ensanut 2012, the proportion of vaccinated subjects according to age group and biologic was as follows: adults aged 20-59 years, tetanus: 66.87 vs. 78.08%; women of childbearing age, tetanus: 71.1 vs. 82.0%; measles/rubella: 36.8 vs. 48.5%; older adults, tetanus: 59.5 vs. 65.86%; influenza: 58.7 vs. 51.9%; pneumococcus: 34.8 vs. 45.9%. Covid-19 vaccine coverage in younger and older adults was 86.6 and 89.2%, respectively. Incomplete schedules were more prevalent in men and in people without health insurance, among adults aged 20 to 59; and in people without health insurance, among adults aged 60 years or older. Discussion. A considerable proportion of adults and older adults are not protected against vaccinepreventable diseases in 2021-2023.

REFERENCES

1. World Health Organization. Global vaccine action plan 2011-2020. Ginebra:WHO, 2013 [citado marzo, 2023]. Disponible en: https://www.who.int/publications/i/item/global-vaccine-action-plan-2011-2020

2. World Health Organization. Immunization Agenda 2030: a global strategyto leave no one behind. Ginebra: WHO, 2020 [citado marzo, 2023].Disponible en: http://www.who.int/fr/publications/m/item/immunizationagenda-2030-a-global-strategy-to-leave-no-one-behind

3. Gobierno de México. Manual de vacunación. México 2021. México:Secretaría de Salud, 2021 [citado marzo, 2023]. Disponible en:https://www.gob.mx/salud/censia/es/articulos/manual-de-vacunacion-2021-295402?idiom=es

4. Romero-Martínez M, Barrientos-Gutiérrez T, Cuevas-Nasu L, Bautista-Arrendondo S, Colchero MA, Gaona-Pineda EB, et al. Metodología de laEncuesta Nacional de Salud y Nutrición 2022 y planeación y diseño dela Ensanut Continua 2020-2024. Salud Publica Mex. 2022; 64(5):522-9.https://doi.org/10.21149/14186

5. Bonanni P, Sacco C, Donato R, Capei R. Lifelong vaccination as a keydisease-prevention strategy. Clin Microbiol Infect. 2014;20(supl 5):32-6.https://doi.org/10.1111/1469-0691.12537

6. Doherty TM, Connolly MP, Del Giudice G, Flamaing J, Goronzy JJ,Grubeck-Loebenstein B, et al. Vaccination programs for older adults in anera of demographic change. Eur Geriatr Med. 2018;9:289-300. https://doi.org/10.1007/s41999-018-0040-8

7. Diario Oficial de la Federación. Norma Oficial Mexicana NOM-036-SSA2-2012, prevención y control de enfermedades. Aplicación de vacunas,toxoides, faboterápicos (sueros) e inmunoglobulinas en el humano.México: DOF, 28 de septiembre de 2012 [citado marzo, 2023]. Disponibleen: https://dof.gob.mx/nota_detalle.php?codigo=5270654&fecha=28/09/2012#gsc.tab=0

8. Hoover DR, Sambamoorthi U, Crystal S. Characteristics of communitydwelling elderly not vaccinated for pneumococcus in 1998 and 2001. PrevMed. 2004;39(3):517-27. https://doi.org/10.1016/j.ypmed.2004.02.009

9. Gavazzi G, Wazieres B, Lejeune B, Rothan-Tondeur M. Influenza andpneumococcal vaccine coverages in geriatric health care settings in France.Gerontology. 2008;53(6):382-7. https://doi.org/10.1159/000105166

10. Lafond KE, Porter RM, Whaley MJ, Suizan Z, Ran Z, Aleem MA, et al.Global burden of influenza-associated lower respiratory tract infections andhospitalizations among adults: A systematic review and meta-analysis. PLoSMed. 2021;18(3):e1003550. https://doi.org/10.1371/journal.pmed.1003550

11. GBD 2019 LRI Collaborators. Age-sex differences in the globalburden of lower respiratory infections and risk factors, 1990-2019:results from the Global Burden of Disease Study 2019. Lancet Infect Dis.2022;22(11):1626-47. https://doi.org/10.1016/S1473-3099(22)00510-2

12. World Health Organization. Considerations for penumococcalvaccination in older adults. Guideline. WHO, 2021 [citado marzo, 2023].Disponible en: https://www.who.int/publications/i/item/WER9623-217-228

13. Lu PJ, Hung MC, Srivastav A, Grohskopf LA, Kobayashi M, HarrisAM, et al. Surveillance of vaccination coverage among adult populations-United States, 2018. MMWR Surveill Summ. 2021;70(3):1-26. https://doi.org/10.15585/mmwr.ss7003a1

14. King JP, McLean HQ, Belongia EA. Validation of self-reported influenzavaccination in the current and prior season. Influenza Other Respir Viruses.2018;12(6):808-13. https://doi.org/10.1111/irv.12593

15. MacDonald R, Baken L, Nelson A, Nichol KL. Validation of self-report ofinfluenza and pneumococcal vaccination status in elderly outpatients. Am JPrev Med. 1999;16(3):173-7. https://doi.org/10.1016/s0749-3797(98)00159-7

16. Rolnick SJ, Parker ED, Nordin JD, Hedblom BD, Wei F, Kerby T, et al.Self-report compared to electronic medical record across eight adult vaccines:Do results vary by demographic factors? Vaccine. 2013;31(37):3928-35. https://doi.org/10.1016/j.vaccine.2013.06.041

17. Zimmerman RK, Raymund M, Janosky JE, Nowalk MP, Fine MJ. Sensitivityand specificity of patient self-report of influenza and pneumococcalpolysaccharide vaccinations among elderly outpatients in diverse patientcare strata. Vaccine. 2003;21(13-14):1486-91. https://doi.org/10.1016/s0264-410x(02)00700-4

18. Organización Panamericana de la Salud. La inmunización a lo largo delcurso de vida. OPS, 2024 [citado julio, 2024] Disponible en: https://www.paho.org/es/temas/inmunizacion/centro-recursos-sobre-inmunizacion-lolargo-curso-vida